Search
Iowa Paid Clinical Trials
A listing of 798 clinical trials in Iowa actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
577 - 588 of 798
Iowa is currently home to 798 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and West Des Moines. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
DIAMOND AF Post-Approval Study
Recruiting
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Iowa Heart Center (West Des Moines IA), West Des Moines, Iowa
Conditions: Paroxysmal Atrial Fibrillation
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Follow-up Visit of High Risk Infants
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Vertebral Artery Stenosis
Tenapanor in Synucleinopathy-Related Constipation
Recruiting
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
02/06/2025
Locations: Cedar Valley Digestive Health Center, Waterloo, Iowa
Conditions: Synucleinopathy, Parkinson's Disease
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: The Iowa Clinic, West Des Moines, Iowa
Conditions: COPD
IV vs Epidural Opioids + Epidural Local Anesthetic for Laparotomy Analgesia
Recruiting
The purpose of this research study is to determine if the two common ways of administering additional opioids (morphine like substance, narcotic) with an epidural, either mixed in the epidural solution or given separately through the intravenous, are equally effective in controlling post-operative pain
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/04/2025
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Laparotomy
Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
Recruiting
Comparison of post-operative pain after total shoulder surgery. The Principle Investigator will be comparing Exparel single shot block to Interscalene catheter
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/04/2025
Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa
Conditions: Post Operative Pain, Anesthesia, Nerve Block, Shoulder Osteoarthritis
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Crohn's Disease
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Recruiting
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway.
A multicenter, randomized, adaptive allocation clinical trial to identify the most... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/30/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Sepsis, Acute Infection, Organ Failure
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases.
The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Spinal Muscular Atrophy (SMA)
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #62, Des Moines, Iowa
Conditions: Head and Neck Squamous Cell Carcinoma